title: Trimethoprim-sulfamethoxazole in the treatment of otitis media caused by ampicillin-resistant strains of Haemophilus influenzae.
abstract: Trimethoprim-sulfamethoxazole (TMP-SMZ) was successful treatment for 93% of cases of acute otitis media caused by ampicillin-resistant Haemophilus influenzae studied. All 15 children in this study had symptoms of otitis media that were unrelieved by a course of ampicillin therapy, but 14 of them responded promptly to a 10-day course of TMP-SMZ. Potentially invasive type b strains of H. influenzae were isolated in cultures of the middle ear exudate of three children, all of whom responded well to TMP-SMZ therapy. The middle ear isolates of H. influenzae were sensitive in vitro to TMP-SMZ. It is concluded that TMP-SMZ is effective and convenient for the treatment of otitis media caused by ampicillin-resistant H. influenzae.
mesh_terms: D000667:Ampicillin / Q000494:pharmacology*; D002675:Child, Preschool; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy*; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007223:Infant; D008297:Male; D010033:Otitis Media / Q000188:drug therapy* / Q000382:microbiology; D010403:Penicillin Resistance; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
chemical_list: D004338:Drug Combinations; D000667:Ampicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole